This report includes information previously submitted as part of the alternative summary report filed on 2016-april-28 by medtronic under expired asr reporting authorization number (b)(4) and includes supplemental information received by medtronic.Any additional information received regarding this device report will be submitted as a supplement to this report.Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Any required fields that are unpopulated are blank because the information is currently unknown or unavailable.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
Medtronic received information that thirteen years, three months post implant of this bioprosthetic valve, this valve was replaced valve-in-valve with a medtronic transcatheter valve due to elevated gradients resulting from aortic stenosis (as).No adverse patient effects were reported.Additional information was received that reported after an unknown duration post implant of the 25mm aortic bioprosthetic valve, it was explanted and replaced with another manufacturers product.The reason for replacement was not reported.No additional adverse patient effects were reported.
|